ClinicalTrials.gg
CompletedNCT02217410Updated Sep 28, 2021Results posted

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

A Phase 1/2 interventional study of CFZ533 and Tacrolimus (Tac) in Kidney Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and potential for CFZ533 to replace calcineurin inhibitors (CNI), while providing a similar rate of acute rejection prophylaxis and renal function in a de novo renal transplant population receiving an allograft from standard criteria donors.

02

Conditions studied

  • Kidney Transplantation

Keywords

  • renal, de novo,
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Written must be obtained before any assessment is performed.
  • Recipients of a kidney transplant from a heart-beating deceased, living unrelated or non-human leukocyte antigen (HLA) identical living related donor.
  • Recipients of a kidney with a cold ischemia time (CIT) \< 30 hours.

Main Exclusion Criteria:

  • Recipients of an organ from a non-heart beating donor.
  • ABO incompatible or complement-dependent lymphocytotoxic (CDC) crossmatch positive transplant.
  • Subjects receiving a second kidney allograft, unless the first allograft was lost due to surgical complication.
  • Subjects at high immunological risk for rejection
  • Subjects at risk for tuberculosis (TB)
  • Subject with severe systemic infections, current or within the two weeks prior to randomization/enrollment.
  • Any additional to the use of tacrolimus or mycophenolate mofetil according to the national labeling information of these products (see local product label).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Regimen A

    CFZ533 administered with the contemporary standard of care (SoC) consists of concentration-controlled tacrolimus (Tac), combined with mycophenolate mofetil (MMF) and corticosteroids (CS).

    Biological: CFZ533 · Drug: Tacrolimus (Tac) · Drug: Mycophenolate mofetil (MMF) · Drug: Corticosteroids (CS)

  • Experimental
    Regimen B

    CFZ533 administered with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction

    Biological: CFZ533 · Drug: Mycophenolate mofetil (MMF) · Drug: Corticosteroids (CS) · Biological: anti-IL2 Induction

  • Active comparator
    Regimen C

    Standard of care (SoC) \[concentration-controlled tacrolimus (Tac) combined with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction\]

    Drug: Tacrolimus (Tac) · Drug: Mycophenolate mofetil (MMF) · Drug: Corticosteroids (CS) · Biological: anti-IL2 Induction

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Cmax Pharmacokinetic Parameter- Part I

    Pharmacokinetics as defined by the systemic concentrations and Cmax of certain immunosuppressant medications used in Part I

    Time frame: Day 1

  2. Mean Tmax Pharmacokinetic Parameter - Part I

    Quantify pharmacokinetics of CFZ533 in combination with MMF, CS, and tacrolimus in de novo renal transplant patients during the treatment and follow-up periods.

    Time frame: Day 1

  3. Mean AUClast Pharmacokinetic Parameter - Part I

    Quantify pharmacokinetics of CFZ533 in combination with MMF, CS, and tacrolimus in de novo renal transplant patients during the treatment and follow-up periods.

    Time frame: Day 1

  4. Efficacy as Defined by the Frequency and Severity (Banff Classification) of Treated Biopsy Proven Acute Rejection (tBPAR) Adjudicated Data - Part II

    To assess the activity of the investigational arm as compared to the standard of care control arm in de novo renal transplant patients as measured by the frequency and severity of tBPAR as measured on the Banff classification scale. An adjudication was performed on all on cause renal biopsies by an independent expert committee blinded to therapy.

    Time frame: 3, 6, 9, and 12 months

Secondary outcomes

  1. Total Soluble CD40 and Total Soluble CD154 Concentrations in Plasma - Part 1

    To quantify the change from baseline and recovery of peripheral blood total soluble CD40 and total soluble CD154

    Time frame: Baseline to end of study (Day 1, Day 29, Day 337)

  2. Free CD40 and Total CD40 on B Cells - Part II

    The magnitude and duration of peripheral blood CD40 occupancy. MESF: molecules of equivalent soluble fluorochrome

    Time frame: Baseline to end of study (Day 1/predose)

  3. Anti-CFZ533 Antibodies - Part I

    To evaluate the immunogenicity of CFZ533 via the quantitative analysis of anti-CFZ533 antibodies

    Time frame: Baseline to end of study

  4. Anti-CFZ533 Antibodies - Part II

    To evaluate the immunogenicity of CFZ533 via the quantitative analysis of anti-CFZ533 antibodies

    Time frame: Baseline to end of study (screening, baseline, Day 141, Day 225, Day 309, Study Completion)

  5. eGFR - Part II

    Renal function as assessed by MDRD (Modification of Diet in Renal Disease) formula. eGFR: Estimated glomerular filtration rate

    Time frame: Day 1, Day 29, Day 337,

  6. CFZ533 Plasma PK Concentrations - Part II

    Quantify the systemic concentrations of CFZ533 in combination with MMF, CS, and tacrolimus in de novo renal transplant patients during the treatment and follow-up periods. A full pharmacokinetic analysis can be performed on the concentration-time data to evaluate the impact of renal transplantation on the various medications used in the treatment regimen.

    Time frame: throughout study period (day 84 to day 336)

  7. Total sCD40 Plasma Concentrations - Part II

    To quantify the change from baseline and recovery of peripheral blood total soluble CD40

    Time frame: 12 months

07

Results

Posted Dec 21, 2018

Participant flow

In Part 1, patients were enrolled into Arm 1. In Part 2, patients were randomized (2:1) to Arms 2A and 2B.

Participant flow — Overall Study
MilestoneCFZ533 + TAC + MMF (Part 1)CFZ533 + MMF (Part 2)Tac + MMF (Part 2)
Started73418
Completed63013
Not completed145
Withdrew: Graft loss002
Withdrew: Withdrawal by subject002
Withdrew: Lost to follow-up001
Withdrew: Lack of efficacy010
Withdrew: Physician decision130

Outcome measures

PrimaryMean Cmax Pharmacokinetic Parameter- Part I

Pharmacokinetics as defined by the systemic concentrations and Cmax of certain immunosuppressant medications used in Part I

Time frame:
Day 1
Reported as:
Mean · ug/mL
Mean Cmax Pharmacokinetic Parameter- Part I
ug/mLCFZ533 + TAC + MMF (Part 1)
Mean Cmax Pharmacokinetic Parameter- Part I66.3 ± 12.3
PrimaryMean Tmax Pharmacokinetic Parameter - Part I

Quantify pharmacokinetics of CFZ533 in combination with MMF, CS, and tacrolimus in de novo renal transplant patients during the treatment and follow-up periods.

Time frame:
Day 1
Reported as:
Median · day
Mean Tmax Pharmacokinetic Parameter - Part I
dayCFZ533 + TAC + MMF (Part 1)
Mean Tmax Pharmacokinetic Parameter - Part I0.237 (0 to 1.02)
PrimaryMean AUClast Pharmacokinetic Parameter - Part I

Quantify pharmacokinetics of CFZ533 in combination with MMF, CS, and tacrolimus in de novo renal transplant patients during the treatment and follow-up periods.

Time frame:
Day 1
Reported as:
Mean · day*ug/mL
Mean AUClast Pharmacokinetic Parameter - Part I
day*ug/mLCFZ533 + TAC + MMF (Part 1)
Mean AUClast Pharmacokinetic Parameter - Part I367 ± 52.0
PrimaryEfficacy as Defined by the Frequency and Severity (Banff Classification) of Treated Biopsy Proven Acute Rejection (tBPAR) Adjudicated Data - Part II

To assess the activity of the investigational arm as compared to the standard of care control arm in de novo renal transplant patients as measured by the frequency and severity of tBPAR as measured on the Banff classification scale. An adjudication was performed on all on cause renal biopsies by an independent expert committee blinded to therapy.

Time frame:
3, 6, 9, and 12 months
Reported as:
Number · events
Efficacy as Defined by the Frequency and Severity (Banff Classification) of Treated Biopsy Proven Acute Rejection (tBPAR) Adjudicated Data - Part II
eventsCFZ533 + MMF (Part 2)Tac + MMF (Part 2)
Month 362
Month 673
Month 973
Month 1273
Statistical analysis
  • CFZ533 + MMF (Part 2) vs Tac + MMF (Part 2) · Bayesian posterior probability · p = 0.8976 · Mean difference (final values): 0.095 · 95% CI -0.067 to 0.263Month 3
  • CFZ533 + MMF (Part 2) vs Tac + MMF (Part 2) · Bayesian posterior probability · p = 0.8836 · Mean difference (final values): 0.093 · 95% CI -0.084 to 0.271Month 6
  • CFZ533 + MMF (Part 2) vs Tac + MMF (Part 2) · Bayesian posterior probability · p = 0.8822 · Mean difference (final values): 0.093 · 95% CI -0.085 to 0.272Month 9
  • CFZ533 + MMF (Part 2) vs Tac + MMF (Part 2) · Bayesian posterior probability · p = 0.8821 · Mean difference (final values): 0.093 · 95% CI -0.087 to 0.273Month 12
SecondaryTotal Soluble CD40 and Total Soluble CD154 Concentrations in Plasma - Part 1

To quantify the change from baseline and recovery of peripheral blood total soluble CD40 and total soluble CD154

Time frame:
Baseline to end of study (Day 1, Day 29, Day 337)
Reported as:
Mean · ng/ml
Total Soluble CD40 and Total Soluble CD154 Concentrations in Plasma - Part 1
ng/mlsCD40 (Part I)sCD154
Baseline4.03 ± 4.080.125 ± 0.007
Day 18.86 ± 0.05850.0585 ± 0.0711
Day 216.7 ± 4.510.139 ± 0.193
Day 324.8 ± 4.470.157 ± 0.235
Day 431.3 ± 6.340.241 ± 0.418
Day 854.0 ± 11.20.399 ± 0.636
Day 1584.1 ± 13.80.0879 ± 0.139
Day 22102 ± 13.90.0500 ± 0.132
Day 29120 ± 15.70.225 ± 0.504
Day 36128 ± 19.20.116 ± 0.2
Day 43145 ± 25.60.0193 ± 0.0474
Day 50156 ± 6.350.0478 ± 0.0687
Day 57161 ± 21.20 ± 0
Day 64163 ± 24.20.0316 ± 0.0492
Day 71156 ± 19.20.0148 ± 0.0363
Day 85168 ± 21.40.0139 ± 0.0340
Day 99155 ± 23.30 ± 0
Day 11385.7 ± 47.90.0668 ± 0.164
Day 12712.2 ± 15.70.0488 ± 0.0697
EoS0.918 ± 0.3300.0184 ± 0.0411
SecondaryFree CD40 and Total CD40 on B Cells - Part II

The magnitude and duration of peripheral blood CD40 occupancy. MESF: molecules of equivalent soluble fluorochrome

Time frame:
Baseline to end of study (Day 1/predose)
Reported as:
Mean · MESF
Free CD40 and Total CD40 on B Cells - Part II
MESFFree CD40 on Whole Blood B CeelsTotal CD40 on Whole Blood B Cells
CFZ553 + MMF (Baseline)30836.00 ± 13648.6912778.80 ± 7873.76
CFZ553 + MMF (D1 - 6h post dose)1623.81 ± 1359.8513806.90 ± 7185.66
CFZ553 + MMF (D15)799.62 ± 762.3815160.38 ± 7398.57
CFZ553 + MMF (D 29)817.63 ± 1540.1613299.60 ± 6330.89
CFZ553 + MMF (D 57)597.13 ± 523.5512234.38 ± 6943.13
CFZ553 + MMF (D 85)635.47 ± 614.689330.86 ± 8484.46
CFZ553 + MMF (D 197)3699.0 ± 7298.982820.72 ± 2347.11
CFZ553 + MMF (253)2667.38 ± 6146.861427.14 ± 740.48
CFZ553 + MMF (EoS)176.17 ± 266.821069.67 ± 809.12
Tac + MMF (Baseline)31508.33 ± 12759.4914581.43 ± 9342.79
Tac + MMF (D1 - 6h post dose)26437.65 ± 11930.5013715.00 ± 8293.33
Tac + MMF (D15)24441.67 ± 9125.9313707.14 ± 6770.14
Tac + MMF (D29)27840.00 ± 12106.7212698.75 ± 6002.96
Tac + MMF (D57)27994.29 ± 12004.5712583.85 ± 6210.07
Tac + MMF (D85)25044.00 ± 10896.658701.54 ± 4183.00
Tac + MMF (D197)21360.00 ± 3155.672067.60 ± 1617.28
Tac + MMF (D253)15752.75 ± 7145.321750.50 ± 1005.84
Tac + MMF (EoS)21200.00 ± 4407.956276.17 ± 11271.20
SecondaryAnti-CFZ533 Antibodies - Part I

To evaluate the immunogenicity of CFZ533 via the quantitative analysis of anti-CFZ533 antibodies

Time frame:
Baseline to end of study
Reported as:
Number · anti-CFZ533 antibodies
Anti-CFZ533 Antibodies - Part I
anti-CFZ533 antibodiesCFZ533 + TAC + MMF (Part 1)
Anti-CFZ533 Antibodies - Part I0
SecondaryAnti-CFZ533 Antibodies - Part II

To evaluate the immunogenicity of CFZ533 via the quantitative analysis of anti-CFZ533 antibodies

Time frame:
Baseline to end of study (screening, baseline, Day 141, Day 225, Day 309, Study Completion)
Reported as:
Number · anti-CFZ533 antibodies
Anti-CFZ533 Antibodies - Part II
anti-CFZ533 antibodiesCFZ533 + MMF (Part 2)Tac + MMF (Part 2)
Screening00
Baseline0—
Day 14100
Day 22500
Day 30900
Study Completion00
SecondaryeGFR - Part II

Renal function as assessed by MDRD (Modification of Diet in Renal Disease) formula. eGFR: Estimated glomerular filtration rate

Time frame:
Day 1, Day 29, Day 337,
Reported as:
Mean · ml/min
eGFR - Part II
ml/minCFZ533 + MMF (Part 2)Tac + MMF (Part 2)
Day 19.8 (8.3 to 11.3)9.7 (7.7 to 11.8)
Day 2955.6 (50.4 to 60.7)44.3 (37.2 to 51.4)
Day 33758.2 (52.2 to 64.2)44.2 (36.1 to 52.3)
SecondaryCFZ533 Plasma PK Concentrations - Part II

Quantify the systemic concentrations of CFZ533 in combination with MMF, CS, and tacrolimus in de novo renal transplant patients during the treatment and follow-up periods. A full pharmacokinetic analysis can be performed on the concentration-time data to evaluate the impact of renal transplantation on the various medications used in the treatment regimen.

Time frame:
throughout study period (day 84 to day 336)
Reported as:
Mean · ug/mL
CFZ533 Plasma PK Concentrations - Part II
ug/mLCFZ533 + MMF (Part 2)
Day 84247 ± 58.2
Day 112211 ± 51.8
Day 140178 ± 54.9
Day 168157 ± 57.4
Day 196148 ± 53.1
Day 224147 ± 53.8
Day 252151 ± 35.2
Day 280160 ± 87.7
Day 308132 ± 42.5
Day 336156 ± 85.2
End of study133 ± 57.8
SecondaryTotal sCD40 Plasma Concentrations - Part II

To quantify the change from baseline and recovery of peripheral blood total soluble CD40

Time frame:
12 months
Reported as:
Mean · ng/mL
Total sCD40 Plasma Concentrations - Part II
ng/mLCFZ533 + MMF (Part 2)Tac + MMF (Part 2)
Baseline3.02 ± 2.443.67 ± 2.15
Day 16.95 ± 4.291.16 ± 1.15
Day 424.6 ± 11.01.16 ± 1.15
Day 1569.6 ± 21.50.869 ± 1.55
Day 29101 ± 18.90.362 ± 0.0746
Day 57140 ± 17.40.438 ± 0.316
Day 85189 ± 76.40.429 ± 0.324
Day 113215 ± 75.50.391 ± 0.129
Day 141237 ± 93.10.453 ± 0.271
Day 169238 ± 80.30.537 ± 0.215
Day 197253 ± 81.30.423 ± 0.0908
Day 225258 ± 77.70.452 ± 0.119
Day 253236 ± 36.50.457 ± 0.0800
Day 281273 ± 71.30.455 ± 0.0789
Day 309286 ± 66.00.454 ± 0.0957
Day 337298 ± 57.40.411 ± 0.0581
End of Study303 ± 59.70.959 ± 1.88

Adverse events

Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 3 years.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CFZ533 + TAC + MMF (Part 1)0/7 (0%)4/7 (57.1%)7/7 (100%)
CFZ533 + MMF (Part 2)0/34 (0%)21/34 (61.8%)33/34 (97.1%)
Tac + MMF (Part 2)0/18 (0%)12/18 (66.7%)18/18 (100%)
Total0/59 (0%)37/59 (62.7%)58/59 (98.3%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventCFZ533 + TAC + MMF (Part 1)CFZ533 + MMF (Part 2)Tac + MMF (Part 2)Total
VomitingGastrointestinal disorders2/70/341/183/59
PyelonephritisInfections and infestations0/72/343/185/59
Kidney transplant rejectionImmune system disorders0/75/341/186/59
PhotophobiaEye disorders1/70/340/181/59
Vision blurredEye disorders1/70/340/181/59
Abdominal painGastrointestinal disorders1/71/340/182/59
DiarrhoeaGastrointestinal disorders1/71/341/183/59
Mouth ulcerationGastrointestinal disorders1/70/340/181/59
NauseaGastrointestinal disorders1/70/340/181/59
PancreatitisGastrointestinal disorders1/70/340/181/59
Most frequent other events
Showing 10 of 307
Most frequent other events
EventCFZ533 + TAC + MMF (Part 1)CFZ533 + MMF (Part 2)Tac + MMF (Part 2)Total
HypophosphataemiaMetabolism and nutrition disorders5/711/345/1821/59
NauseaGastrointestinal disorders4/710/349/1823/59
DiarrhoeaGastrointestinal disorders2/78/3410/1820/59
ConstipationGastrointestinal disorders1/714/348/1823/59
Wound complicationInjury, poisoning and procedural complications0/711/348/1819/59
VomitingGastrointestinal disorders3/78/344/1815/59
Secretion dischargeGeneral disorders3/70/340/183/59
BK virus infectionInfections and infestations3/710/346/1819/59
Incision site painInjury, poisoning and procedural complications3/76/342/1811/59
HyperglycaemiaMetabolism and nutrition disorders3/74/344/1811/59

Baseline characteristics

The Safety Analysis Set included all patients that received at least one dose of study drug. For Part 2, all patients that received their transplant along with any patient who received study drug but had no transplant were combined.

Age, Continuous
Age, Continuous(years)CFZ533 + TAC + MMF (Part 1)CFZ533 + MMF (Part 2)Tac + MMF (Part 2)Total
Mean48.1 ± 9.3049.0 ± 15.7953.4 ± 18.0150.1 ± 15.91
Sex: Female, Male
Sex: Female, Male(Participants)CFZ533 + TAC + MMF (Part 1)CFZ533 + MMF (Part 2)Tac + MMF (Part 2)Total
Female38617
Male4261242
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CFZ533 + TAC + MMF (Part 1)CFZ533 + MMF (Part 2)Tac + MMF (Part 2)Total
Hispanic or Latino0101
Not Hispanic or Latino220931
Unknown or Not Reported513927
08

Study locations

14 sites
  • Novartis Investigative Site
    Aurora, Colorado 80045, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21201, United States
  • Novartis Investigative Site
    Ann Arbor, Michigan 48109 5271, United States
  • Novartis Investigative Site
    Detroit, Michigan 48202, United States
  • Novartis Investigative Site
    Livingston, New Jersey 07039, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45267-0585, United States
  • Novartis Investigative Site
    São Paulo, SP 04038-002, Brazil
  • Novartis Investigative Site
    Berlin, D-13353, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Utrecht, The Netherlands 3508 GA, Netherlands
  • Novartis Investigative Site
    Groningen, 9713 GZ, Netherlands
  • Novartis Investigative Site
    Rotterdam, 3000 CA, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Nov 2017, 33 months.

Results were first posted in Dec 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2014
First posted
Aug 15, 2014
StartActual
Feb 5, 2015
Primary completionActual
Nov 29, 2017
CompletionActual
Nov 29, 2017
Results first posted
Dec 21, 2018
Last update
Sep 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02217410
Responsible party
Sponsor
First posted
Aug 15, 2014
Start date
Feb 5, 2015
Primary completion
Nov 29, 2017
Completion
Nov 29, 2017
Results posted
Dec 21, 2018
Last update
Sep 28, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iscalimab · Tacrolimus

Start the discussion